.Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01C_HypothalamicHormones.H01CC04_Linzagolix.Linzagolix .Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01C_HypothalamicHormones.H01CC04_Linzagolix.Linzagolix| name: | Linzagolix |
| ATC code: | H01CC04 | route: | oral |
| n-compartments | 2 |
Linzagolix is an oral, selective, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist used for the treatment of uterine fibroids and endometriosis in women of reproductive age. It reduces estrogen levels by suppressing the hypothalamic-pituitary-gonadal axis. Linzagolix is approved in the European Union but not in the United States.
Pharmacokinetic parameters reported in healthy premenopausal women after oral administration.